Sugi Predict

Sugi Predict / Compounds / SCHEMBL1348752

SCHEMBL1348752

SCHEMBL1348752

CCOC(=O)C(=CNC1CC1)C(=O)c1c(F)c(F)cc(F)c1F

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.39
▸ MAPT P10636 4/20 0.37
▸ MEN1 O00255 4/20 0.37
▸ KMT2A Q03164 4/20 0.37
▸ NPSR1 Q6W5P4 2/20 0.37
▸ LMNA P02545 2/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ DHODH Q02127 3/20 0.36
▸ GAA P10253 4/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ CYP2D6 P10635 2/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ CYP3A4 P08684 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.33
▸ MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1348749 1.00 POLB (0.39) POLBMAPTMEN1KMT2ANPSR1
SCHEMBL9501196 0.93 NPSR1 (0.36) POLBMAPTMEN1KMT2ANPSR1
SCHEMBL5505216 0.92 POLB (0.37) POLBMAPTMEN1KMT2ANPSR1
SCHEMBL5505218 0.92 POLB (0.37) POLBMAPTMEN1KMT2ANPSR1
SCHEMBL1345392 0.90 CYP2D6 (0.38) MAPTMEN1KMT2ANPSR1LMNA
SCHEMBL9562436 0.90 CYP2D6 (0.38) MAPTMEN1KMT2ANPSR1LMNA
SCHEMBL1345391 0.90 CYP2D6 (0.38) MAPTMEN1KMT2ANPSR1LMNA
SCHEMBL9562430 0.87 NPSR1 (0.36) POLBMAPTMEN1KMT2ANPSR1
SCHEMBL10400402 0.87 NPSR1 (0.36) POLBMAPTMEN1KMT2ANPSR1
SCHEMBL7049477 0.87 NPSR1 (0.36) POLBMAPTMEN1KMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063066-B2 MAPK/ERK kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-11-22 — — US disclosed
US-8063066-B2 MAPK/ERK kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-11-22 — — US disclosed
US-8063066-B2 MAPK/ERK kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-11-22 — — US disclosed
EP-2150544-A2 MAPK/ERK KINASE INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2010-02-10 — — EP disclosed
US-20090118324-A1 MAPK/ERK KINASE INHIBITORS TAKEDA SAN DIEGO, INC. 2009-05-07 — — US disclosed
US-20090118324-A1 MAPK/ERK KINASE INHIBITORS TAKEDA SAN DIEGO, INC. 2009-05-07 — — US disclosed
US-20090118324-A1 MAPK/ERK KINASE INHIBITORS TAKEDA SAN DIEGO, INC. 2009-05-07 — — US disclosed
WO-2008115890-A2 MAPK/ERK KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-09-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118324-A1 MAPK/ERK KINASE INHIBITORS MAPK1, MAP3K1, MAP3K7 POLB 1594/4885MAPT 1570/4885MEN1 1220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.